The European Medicines Agency shall provide the HTA secretariat with:
information on all medical devices for which the expert panels designated in accordance with Article 106(1) of Regulation (EU) 2017/745 have provided or have decided to provide a scientific opinion in the framework of the clinical evaluation consultation procedure pursuant to Article 54 of that Regulation;
information on all in vitro diagnostic medical devices for which the expert panel has provided or has been asked to provide its views in the framework of the procedure pursuant to Article 48(6) of Regulation (EU) 2017/746.
The information referred to in the first subparagraph, point (a), shall include the following elements:
the name and type of the device;
the name of the manufacturer;
the name of the notified body;
the expert panel decision regarding the intention to provide a scientific opinion referred to in Section 5.1, point (c), of Annex IX to Regulation (EU) 2017/745;
where available, the scientific opinion of the expert panel.
The information referred to in the first subparagraph, point (b), shall include the following elements:
the name and type of the in vitro diagnostic medical device;
the name of the manufacturer;
the name of the notified body;
where available, the views of the expert panel.
The European Medicines Agency shall provide the information referred to in paragraph 1 no later than 15 days after the end of each quarter, pertaining to that quarter. For the first reporting period, the European Medicines Agency shall provide the information referred to in paragraph 1 covering the period from 1 January 2024.